Development and Method Validation of Design of Experiments-Optimized Tablet Formulation for Simultaneous Detection of Exemestane and Everolimus

Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor‐Positive Breast Cancer Previously Treated with CDK4 /6 Inhibitor Therapy

(2020) Madeline M. Cook et al.   ONCOLOGIST

The Significance of Disintegration Testing in Pharmaceutical Development

(2018) Daniela Amaral Silva et al.   DISSOLUTION TECHNOLOGIES

Quality by design (QbD) approaches in current pharmaceutical set-up

(2018) Vijay Mishra et al.   Expert Opinion on Drug Delivery

Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations

(2016) Sander Greenland et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer

(2012) Julia A Beaver et al.   Future Oncology

Development and validation of new discriminative dissolution method for carvedilol tablets

(2012) K. V. R. Murthy et al.   INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES

Exemestane as First-Line Therapy in Postmenopausal Women With Recurrent or Metastatic Breast Cancer

(2010) Stefan Glück   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS